Associated Papers
Targeting PCSK9 to tackle cardiovascular disease.
Hummelgaard S et al.
Pharmacology & Therapeutics, 2023
Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review.
Yow HY et al.
Asian Biomedicine : Research, Reviews and News, 2023
Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease.
Chiang SM et al.
The Journal of International Medical Research, 2020
Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 are Associated with Serum Lipid Profile in Chinese Han Population.
Li Z et al.
International Journal of Environmental Research and Public Health, 2019
Evaluation of PCSK9 levels and its genetic polymorphisms in women with polycystic ovary syndrome.
Xavier LB et al.
Gene, 2018
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants.
Dron JS et al.
Current Opinion in Lipidology, 2017
Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study.
Zambrano T et al.
International Journal of Clinical and Experimental Medicine, 2015
Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.
Mayne J et al.
Lipids in Health and Disease, 2013
Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
Huijgen R et al.
Human Mutation, 2012
Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.
Calandra S et al.
Journal of Lipid Research, 2011
Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.
Norata GD et al.
Atherosclerosis, 2010
Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.
Huang CC et al.
Circulation. Cardiovascular Genetics, 2009
The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Scartezini M et al.
Clinical Science (london, England : 1979), 2007
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
Kotowski IK et al.
American Journal of Human Genetics, 2006
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
Chen SN et al.
Journal of the American College of Cardiology, 2005
Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
Anderson JM et al.
Journal of Clinical Lipidology, 0